Guardian Bio

Guardian Bio is a biotechnology company focused on innovating dendritic cell therapy specifically for patients with late-stage solid tumors. The company aims to combine regenerative medicine with immunotherapy to enhance anti-cancer immunity. Through their proprietary technology, Guardian Bio seeks to address the challenges faced in cancer treatment, particularly the impairment of critical immune cells known as cDC1s, which are often disabled by cancer as it progresses. This impairment creates significant hurdles in achieving effective clinical responses in patients.